Makhey Darshan, Li Dajie, Zhao Baoping, Sim Sai Peng, Li Tsai Kun, Liu Angela, Liu Leroy F, LaVoie Edmond J
Department of Pharmaceutical Chemistry, Rutgers, The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, NJ 08854, USA.
Bioorg Med Chem. 2003 Apr 17;11(8):1809-20. doi: 10.1016/s0968-0896(03)00053-1.
Several benzo[c]phenanthridine and protoberberine alkaloids, such as nitidine and berberrubine, are known to induce DNA cleavage in the presence of either topoisomerase I or II. Structure-activity studies performed on various analogues related to benzo[c]phenanthridine and protoberberine alkaloids have provided insights into structural features that influence this topoisomerase-targeting activity. Modifications within the A-ring of benzo[c]phenanthridine and protoberberine alkaloids can significantly alter their ability to enhance the cleavable complex formation that occurs between DNA and topoisomerases. Select benzo[i]phenanthridines were synthesized as potential bioisosteres of nitidine and its analogues. In the present study, 2,3-methylenedioxy-8,9-dimethoxybenzo[i]phenanthridine, 2,3-methylenedioxy-8,9-dimethoxy-5-methylbenzo[i]phenanthridine, 2,3,8,9-tetramethoxybenzo[i]phenanthridine and 5-methyl-2,3,8,9-tetramethoxybenzo[i]phenanthridine were synthesized. These benzo[i]phenanthridine derivatives were evaluated for their ability to enhance cleavable complex formation in the presence of topoisomerases and DNA as well as for their cytotoxicity against the human lymphoblastoma cell line, RPMI8402. 2,3-Methylenedioxy-8,9-dimethoxybenzo[i]phenanthridine (4a) and its 5-methyl derivative (4b) are active as topoisomerase I-targeting agents. In contrast to nitidine, the presence of the 5-methyl substituent in the case of 4b is not associated with enhanced activity. Consistent with previous structure-activity studies on nitidine and protoberberine alkaloids, 2,3,8,9-teramethoxybenzo[i]phenanthridine, 5a, and its 5-methyl derivative, 5b, are inactive as topoisomerase I-targeting agents. These studies were extended to an evaluation of the relative pharmacological activities of 2,8,9-trimethoxybenzo[i]phenanthridine, 3,8,9-trimethoxybenzo[i]phenanthridine, and 2,3-methylenedioxy-8,9-methylenedioxybenzo[i]phenanthridine.
已知几种苯并[c]菲啶和原小檗碱生物碱,如两面针碱和小檗红碱,在拓扑异构酶I或II存在的情况下可诱导DNA裂解。对与苯并[c]菲啶和原小檗碱生物碱相关的各种类似物进行的构效关系研究,为影响这种靶向拓扑异构酶活性的结构特征提供了见解。苯并[c]菲啶和原小檗碱生物碱A环内的修饰可显著改变它们增强DNA与拓扑异构酶之间形成可裂解复合物的能力。合成了一些苯并[i]菲啶作为两面针碱及其类似物的潜在生物电子等排体。在本研究中,合成了2,3-亚甲二氧基-8,9-二甲氧基苯并[i]菲啶、2,3-亚甲二氧基-8,9-二甲氧基-5-甲基苯并[i]菲啶、2,3,8,9-四甲氧基苯并[i]菲啶和5-甲基-2,3,8,9-四甲氧基苯并[i]菲啶。评估了这些苯并[i]菲啶衍生物在拓扑异构酶和DNA存在的情况下增强可裂解复合物形成的能力,以及它们对人淋巴瘤细胞系RPMI8402的细胞毒性。2,3-亚甲二氧基-8,9-二甲氧基苯并[i]菲啶(4a)及其5-甲基衍生物(4b)作为靶向拓扑异构酶I的药物具有活性。与两面针碱不同,在4b的情况下,5-甲基取代基的存在与活性增强无关。与先前对两面针碱和原小檗碱生物碱的构效关系研究一致,2,3,8,9-四甲氧基苯并[i]菲啶(5a)及其5-甲基衍生物(5b)作为靶向拓扑异构酶I的药物无活性。这些研究扩展到对2,8,9-三甲氧基苯并[i]菲啶、3,8,9-三甲氧基苯并[i]菲啶和2,3-亚甲二氧基-8,9-亚甲二氧基苯并[i]菲啶相对药理活性的评估。